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INTRODUCTION 
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can 
be curative in several onco-hematologic diseases, but it is 
burdened by life-threatening complications.1–3 To date, the overall 
incidence of GvHD still remains between 30 and 60% and is 
approximately associated with a 50% mortality rate, especially in 
its severe form.1–3 Its current pathogenesis model represents a 
multiphase process in which the result of the conditioning 
regimen, the release of cytokines and the antigenic differences 
between recipient and donor lead donor lymphocytes to attack 
epithelial cells and mucous membranes in target organs.3 The 
release of cytokines and the immune attack result in ongoing 
tissue damage with further cytokine production and a continuous 
inflammatory positive feedback loop.4 However, T-lymphocytes 
firstly require a tight contact with cells of the vascular 
endothelium to reach the epithelial target organs.5 Therefore, 
the vascular endothelium is currently considered an early phase 
target of donor T-lymphocytes.6–8 During allo-HSCT, endothelial 
cells are affected by a series of events, resulting in endothelial 
damage. In fact, vascular endothelium is highly exposed to toxic 
drugs and inflammatory molecules released in the extracellular 
matrix by damaged cells and leukocytes.9,10 These insults can be 
the initial event of endothelial injury and may contribute to the 
development of immune reactions related to life-threatening 
complications, including GvHD.7,8  Nowadays, validated   non- 
 
invasive biomarkers used in routine clinical practice for GvHD 
diagnosis are lacking. Moreover, laboratory tests can hardly 
predict the risk of developing GvHD or its response to 
treatment.11–14  Thus, the identification of specific   biomarkers 
from peripheral blood (PB) samples would represent a valuable 
tool to avoid invasive diagnostic procedures and help personalize 
treatments after allo-HSCT.15 
In recent years, the direct count of circulating endothelial cells 
(CEC) has emerged as a valuable biomarker of endothelial damage 
in a variety of disorders.8,12,16–20 However, due to their very low 
numbers and complex phenotype, several published techniques 
have shown different degrees of variability, reporting a wide range 
of CEC values (0–7900 CEC/mL) in healthy subjects.12,21–24 We 
prospectively correlated CEC count changes to GvHD onset and 
response to treatment in 90 allo-HSCT patients. Moreover, in this 
study, we used the commercially available rare cell isolation 
platform CellSearch system to identify and count CEC and 
potentially translate results into clinical practice. 
 
 
MATERIAL AND METHODS 
Patients 
During two study periods, June 2011—December 2012 and June 2014— 
October 2015, we prospectively evaluated 90 patients with malignant 
hematologic disorders who underwent allo-HSCT. Moreover, 10 healthy 
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subjects served as controls. In patients and controls, CEC counts were 
performed with the CellSearch system (Janssen Diagnostics LLC, Raritan, 
NJ, USA). CEC were counted, starting from enrollment up to day +100, at 
the following time-points: T1 (pre-conditioning), T2 (pre-transplant), T3 
(engraftment), T4 (day +28 or at onset of GvHD) and T5 (1 week after 
steroid treatment). CEC counts of patients without GvHD at day +28 were 
compared with those reported in patients at the onset of GvHD. In the first 
20 patients, CEC counts were monitored at weekly intervals until day +100. 
Blood samples were drawn from a central catheter to reduce risks of 
endothelial cell contamination due to traumatic damage from venipunc- 
ture. Moreover, the first tube was invariably discarded to avoid accidental 
contamination. Samples were collected by using dedicated tubes (CellSave 
Preservative Tubes, Janssen Diagnostics LLC, Raritan, NJ, USA), stored at 
room temperature and analyzed within 48 h after blood draw.20 The local 
research and ethics committee approved the study protocol and all 
patients provided written informed consent, in accordance with the 
Declaration of Helsinki (ClinicalTrials.gov NCT02064972). 
 
Infections management and GvHD diagnosis 
All patients received levofloxacin until complete neutrophil recovery, 
fluconazole or itraconazole until withdrawn of all immunosuppressive 
drugs, trimethoprim-sulphamethoxazole for Pneumocystis jirovecii pneu- 
monia prevention. CMV infections were monitored weekly by quantitative 
real-time PCR in plasma, and patients tested positive were treated with 
ganciclovir or foscarnet. Fungal infections were evaluated and defined 
according to published revised criteria.25 Diagnosis and grading of GvHD 
were based primarily on clinical findings according to commonly accepted 
diagnostic criteria.26 Whenever possible or clinically indicated, clinical data 
were supported by histopathology studies on tissue biopsies from skin, 
liver and gastrointestinal tract. 
 
CEC identification and count 
CEC counts were performed by means of the Circulating Endothelial Cell 
isolation kit (research use only) in combination with the CellSearch system 
(Janssen Diagnostics LLC, Raritan, NJ, USA), that allows standardization of 
the whole process of sample collection, cellular selection, monoclonal 
antibodies labeling, analysis and enumeration of CEC, as previously 
described.20 To be scored as a CEC, a CD146+ cell must have a nucleus 
(DAPI), express CD105, show the morphology of an intact cell, and be 
negative for CD45. Overall, CEC were defined as CD146+/CD105+/DAPI+/ 
CD45− cells. Counts were expressed as number of CEC per mL of PB. 
 
Statistical analysis 
Mann–Whitney U-test was used in univariate analysis for comparison of 
continuous variables, and χ2 test was used for comparison of categorical 
variables. Multivariate logistic regression analysis was performed at each 
time-point, to assess the independent predictive value of CEC counts in the 
presence of possible interfering factors such as patient and/or transplant- 
related variables and/or infectious events. Analysis of the receiver 
operating characteristics curve was performed to establish a cut-off for 
predictive values of CEC at T3 and T4. CEC counts and their relative 
possible increase/decrease at each time-point (T) were included in all 
analyses. The relative increase of CEC value (%) was expressed using the 
following formula: (CEC at Tx − CEC at T-previous/CEC at T-previous) × 100. 
A mixed model analysis for repeated measures was performed to further 
test differences in CEC counts over time between patients with and 
without GvHD. All P-values were two-sided and P o0.05 was considered 
statistically significant. 
 
RESULTS 
Patients 
Ninety patients, median age 48 years (range 18–69; 52 males/38 
females), who underwent allo-HSCT from either HLA-matched 
familial (n = 20; 22%), unrelated (n = 54; 60%) or haploidentical 
donors (n = 16; 18%) were enrolled. Hematological diseases 
included 37 AML, 15 ALL, 11 HL, four NHL, four CLL, five 
myelodiplastic syndrome, four chronic myeloproliferative syn- 
dromes, eight multiple myeloma and two severe aplastic anemia. 
Forty-eight patients (53%) were in complete response (CR) or 
upfront,  31  patients  (35%)  in  partial  response/CR41  and  11 
patients (12%) in progression at the time of transplant. 
 
Allografting 
Seventy-two patients (80%) received hematopoietic stem cells 
from mobilized PB and 18 (20%) from bone marrow; conditioning 
regimens were myeloablative in 47 patients (52%) and reduced 
intensity in 43 patients (48%). Neutrophil engraftment was 
obtained in 87 patients with a median time to engraftment of 
22 days (range 14–40) whereas two patients died from infection 
and one from transplant-related toxicity during neutropenia. No 
differences in clinical and transplant characteristics were recorded 
between patients with GvHD and those without, with the 
exception of the use of FBu2 as conditioning (P = 0.04) and 
incidence of fungal infections (P = 0.01) (Table 1). Overall, 39/90 
patients (43%) presented with acute GvHD at a median of 24 days 
(range 12–113) post transplant. GvHD was grade I in 10/39 (26%), 
II in 26/39 (67%) and III in 3/39 patients (7%). In 29/39 patients 
(74%) GvHD presented with skin involvement, in 16/39 patients 
(41%) with gut involvement and in 4/39 (10%) with liver 
involvement. 
 
CEC counts pre-transplant 
The median CEC/mL at T1 (pre-conditioning) was 24 (range 2–786) 
as compared with 2 (range 1–14) in healthy controls (P o0.0001) 
(Figure 1). No differences were detected in CEC counts between 
patients with GvHD and those without before (T1, pre-condition- 
ing) and at the end of the conditioning regimen (T2, pre- 
transplant). CEC counts did not change at any time-point 
regardless of age or gender (data not shown). At T1 (pre- 
conditioning) multiple myeloma patients had lower CEC values as 
compared with AL patients (P = 0.004) (Figure 2a), while no 
differences in CEC counts were recorded in relation to disease 
status at transplant (Figure 2b). At T2 (pre-transplant) no 
differences in CEC counts were seen by type of conditioning 
(myeloablative conditioning vs reduced intensity conditioning) 
(Figure 2c), type of HPC donor (Figure 2d) or GvHD prophylaxis 
(Figure 2e). 
 
CEC counts post transplant 
At T3 (engraftment) no differences in CEC counts were seen by 
type of conditioning, donor type, stem cell source or GvHD 
prophylaxis, while multiple myeloma patients had lower CEC 
values as compared with AL (P = 0.01) and lymphoma/CLL patients 
(P = 0.05). Patients with bacterial infections showed lower CEC 
values at T3 time-point (47; range 10–162 vs 84; range 17–436; 
P = 0.001). Median CEC/mL was 57 (range 16–295) in patients with 
GvHD and 91 (range 10–436) in those without GvHD (P = 0.003) 
(Table 2). This difference remained significant by multivariate 
analysis (OR 0.992, 95% CI 0.985–0.99; P = 0.029) (Table 3). At T4 
(day +28 or at onset of GvHD) no differences in CEC counts were 
recorded by donor type, stem cell source or GvHD prophylaxis. 
Myeloablative conditioning was associated with higher CEC values 
as compared with reduced intensity conditioning (P = 0.02). 
Multiple myeloma patients had lower CEC values as compared 
with AL patients (P = 0.003). Patients with documented bacterial 
infections showed lower CEC values at T4 time-point (62; range 
16–135 vs 94; range 13–658; P = 0.001). Median CEC/mL were 71 
(range 13–658) in patients with GvHD and 87 (range 26–436) in 
those without GvHD (P = NS) (Table 2). At GvHD onset (T4), the 
relative increase of CEC counts (T4 vs T3) was 13% (range − 79 to 
723%) in patients with GvHD vs 0% (range − 70 to 332%) in 
patients without GvHD (P = 0.026) (Table 2). This finding was also 
confirmed by multivariate analysis (T4 vs T340%: OR 4.2, 95% CI 
1.6–10.8; P = 0.002) (Table 3). CEC counts inversely correlated with 
acute GvHD grade as follows: at T4 (at onset of GvHD) median 
  
Table 1. Comparison of clinical and transplant characteristics in 
patients with and without acute GvHD (n = 90) 
Characteristics  GvHD (%)     No GvHD (%) P-value 
Age  (years), median (range) 47 (18–67) 49 (18–69) 0.41 
Sex 
1000 
 
 
100 
 
 
10 
 
 
1 
 
 
Diagnosis 
Acute leukemias 24 (62) 28 (55) 0.53 
0.1 
Controls Basal 
Lymphomas/CLL 8 (20) 11 (21) 0.90 
MDS/CMS 2 (5) 7 (14) 0.18 
MM 5 (13) 3 (6) 0.25 
SAA 0 (0) 2 (4) 0.21 
Disease status 
CR/upfronta 21 (54) 27 (53) 0.93 
PR/CR41 14 (36) 17 (33) 0.80 
Progression 4 (10) 7 (14) 0.62 
Donor 
MUD 23 (59) 31 (61) 0.86 
MRD 6 (15) 14 (27) 0.17 
Haploid 10 (26) 6 (12) 0.09 
HPC source 
MPB 32 (82) 40 (78) 0.67 
BM 7 (18) 11 (22) 
Conditioning regimen 
MAC 23 (59) 24 (47) 0.26 
RIC 16 (41) 27 (53) 0.25 
TBI (yes) 9 (23) 7 (14) 
MA conditioning 
BU/CY 7 (18) 13 (25) 0.39 
FBu4 3 (8) 2 (4) 0.44 
TBI/CY 7 (18) 4 (8) 0.15 
TBI/F/Th 2 (5) 1 (2) 0.41 
TBF 4 (10) 4 (8) 0.69 
RIC conditioning 
Th/CY/F 5 (12.5) 7 (14) 0.90 
TBI/F/Th(r) 0 (0) 2 (4) 0.21 
FBu2 0 (0) 5 (10) 0.04 
Th/CY 5 (12.5) 7 (14) 0.90 
TBF(r) 3 (8) 1 (2) 0.19 
Th+F/Cy+F 0 (0) 3 (5) 0.12 
F/Mel/Th 3 (8) 2 (4) 0.44 
GvHD prophylaxisb 
CyA/MTX 29 (74) 44 (86) 0.15 
CyA/MMF 10 (26) 7 (14) 
ATG 20 (51) 28 (55) 0.73 
Bacterial infectionsc 14 (36) 13 (25) 0.29 
Fungal  infectionsc 8 (21) 2 (4) 0.01 
CMV infectionsc 8 (21) 8 (16) 0.53 
Abbreviations: ATG = anti-lymphocyte globulin; BM = bone marrow; BU = busul- 
phan; CMS = chronic myeloproliferative syndromes; CY= cyclophosphamide; 
CyA = Cyclosporin A; F = fludarabine; Haploid = haplodentical related donor; 
HPC = hematopoietic  progenitor  cells;  MAC= myeloablative   conditioning; 
MA = myeloablative; MDS= myelodiplastic syndrome; MM = multiple 
myeloma; MMF = mofetil micofenolate; MPB = mobilized peripheral blood; 
MRD = matched related donor; MTX = methotrexate; MUD = matched unre- 
lated donor; RIC = reduced intensity conditioning; r = RIC; SAA = severe aplastic 
anemia; TBF = Th/BU/F; Th = thiotepa. aUpfront: MDS only. bIn haploidentical 
transplantation GvHD prophylaxis included CyA/MMF and cyclophosphamide 
post stem cell reinfusion  (100 mg/kg  total  dose:  day+3  and  +5).  cBefore  
GvHD onset. Bold values  indicate that they are statistically    significant. 
Figure 1. CEC counts at baseline (T1, pre-conditioning) in patients 
undergoing allo-HSCT in comparison to healthy subjects (controls). 
Boxes represents values from the first to the third quartile, 
horizontal line shows the median value and the whiskers indicate 
the min and max  value. 
 
CEC/mL was 93 (range 46–299) in grade I, 64 (range 13–658) in 
grade II and 36 (range 34–89) in grade III (grade I vs III P = 0.05). No 
significant differences were reported in CEC counts when consider- 
ing skin alone (22/39 patients; 56%) vs gut/liver (17/39 patients; 
44%) involvement (Table 4). Mixed models analysis confirmed the 
correlation between CEC counts and GvHD at T3 (P = 0.004) and the 
increase of CEC values in patients with GvHD from T3 to T4   
(P = 0.001). At T5 (1 week after steroid treatment) median CEC 
counts (48 CEC/mL, range 6–184) returned to pre-transplant values 
(T2, pre-transplant) (44 CEC/mL, range 8–718) (Table 2). 
In receiver operating characteristics analysis, a value of 66 CEC/ 
mL at T3 was 78% specific and 61% sensitive for the development 
of GvHD (area under the curve, AUC = 0.71; P = 0.005). At T4, a 
relative increase 40% of CEC count (T4 vs T3) was 79% specific 
and 53% sensitive (AUC = 0.70). The AUC values demonstrated a 
moderate discriminatory power of the test. Finally, when plotting 
CEC counts over time (weekly determinations) in the first 20 
patients, CEC changes represented a dynamic phenomenon, 
influenced by many variables, but invariably showed an increase 
in CEC counts, starting 1–2 weeks prior to the onset of GvHD, with 
a peak at GvHD diagnosis; the same CEC counts decreased rapidly, 
returning to pre-transplant values, in patients in which steroid 
treatment was able to control GvHD manifestations 
(Supplementary Figure 1). 
 
DISCUSSION 
In recent years, the physio-pathologic interrelationships between 
the endothelium and GvHD have been better elucidated and have 
led to define the entity ‘endothelial GvHD’ as an essential early 
phase prior to the clinical presentation of acute GvHD.5–8 
However, GvHD diagnosis still almost completely relies on clinical 
symptoms, clinicians expertise and should be confirmed by 
histology studies.27 Therefore, the identification of specific 
biomarkers detectable in PB samples could clearly become a 
valuable diagnostic and clinical tool to avoid invasive diagnostic 
procedures such as tissue biopsies. Moreover, it may help 
personalize treatment strategies in GvHD patients. CEC are 
considered specific and sensitive markers of endothelial dysfunc- 
tion and have been used in a variety of pathological conditions to 
monitor vascular damage.12,16–19,28 The commercial availability of 
the CellSearch system for CEC identification and count allows to 
easily monitor CEC changes as a function of endothelial damage in 
allo-HSCT patients.19 Since validated noninvasive biomarkers for 
GvHD diagnosis have not yet routinely been implemented in 
clinical practice,14 we propose the CellSearch system as a valid and 
reliable approach to help/support clinicians in their diagnosis of 
acute GvHD. Since vascular complications have a strong impact on 
the outcome of allo-HSCT, CEC changes have been correlated with 
P <0.0001 
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Figure 2. CEC counts in patients during allo-HSCT. CEC counts at T1 (pre-conditioning) are plotted in graph (a) in relation to diagnosis and in 
graph (b) in relation to disease status at transplant; while CEC counts at T2 (pre-transplant) are plotted in graph (c) in relation to conditioning, 
in graph (d) in relation to HPC donor and in graph (e) in relation to GvHD prophylaxis. Boxes represents values from the first to the third 
quartile, horizontal line shows the median value and the whiskers indicate the min and max value. 
 
the occurrence of endothelial complications. Touzot et al. showed 
that high CEC values are associated with a wide spectrum of 
endothelial complications including sinusoidal obstruction syn- 
drome, thrombotic microangiopathy, capillary leak syndrome and 
pulmonary arterial hypertension in 34 children undergoing allo- 
HSCT for primary immunodeficiency. However, their encouraging 
findings need to be confirmed in larger studies to establish the 
real role of CEC as a biomarker of endothelial damage.29 Not only 
does our study confirm a preliminary report19 but it also 
represents the largest series of allo-HSCT patients where the 
clinical usefulness of CEC changes over time has prospectively 
been correlated to the diagnosis of GvHD and treatment response. 
Although CEC changes in allo-HSCT represent a dynamic 
phenomenon that can be influenced by many variables (among 
others, conditionings, immunosuppressive treatments, engraft- 
ment syndrome, infections), we clearly showed that CEC peaks 
were constantly seen prior to the onset of acute GvHD and 
invariably returned to pre-transplant values after treatment 
response. However, it is important to point out that our  results 
conflict with a previous study conducted in a series of allo- 
HSCT patients by Beije et al.30 This may partly be explained by the 
different CEC count monitoring schedules that may have 
prevented to correlate CEC changes right at the onset of GvHD. 
Undoubtedly, onset of GvHD remains unpredictable over a rather 
long post-transplant period (at least up to day +100/+120 post 
transplant).31 We showed that CEC changes during allo-HSCT had 
a rapid kinetic that may have easily been missed if blood samples 
had been drawn only at given time-points. As a consequence, we 
suggest an ‘on demand’ evaluation of CEC counts right at the 
onset of GvHD clinical symptoms to possibly help differentiate 
GvHD from other non-endothelial complications. Moreover, the 
strength of our study was the use of the CellSearch system that 
guarantees a standardization of CEC counts with high-level 
reproducibility, specificity and sensitivity. Indeed, the CD146 
immunomagnetic selection step, followed by an identification 
strategy based on positive/negative selection criteria, allows 
reduction of analytical variability also when rare events are 
acquired.20 Furthermore, the use of standardized criteria for signal 
intensity and automated image analysis guarantees a better 
reproducibility by reducing inter-operator variability.20 
 /
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 /
 
 
  
Table 3.     Univariate and multivariate analysis to evaluate CEC values  as 
 
 OR (95% CI) P-value 
T3-engraftment 
Univariate analysis 
 
 
 
 
 
1.3 (0.6–3.1) 
2.3 (0.5–10.5) 
 
1.3 (0.5–5.3) 
6.3 (1.2–31.7) 
0.992 (0.985–0.99) 
0.999 (0.998–1.00) 
0.53 
0.26 
0.95 
0.58 
0.03 
 
0.17 
0.992 (0.985–0.99)  
T4-GvHD onset 
Univariate analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnosis of  AL  vs other 1.3 (0.6–3.1) 0.53 
Diagnosis of MM vs  other 2.3 (0.5–10.5) 0.26 
Conditioning RIC (FBu2) vs  other nv 0.95 
MAC vs RIC 1.7 (0.7–4.1) 0.19 
Bacterial infections 1.6 (0.7–4.1) 0.29 
Fungal infections 6.3 (1.2–31.7) 0.03 
CEC relative increase (T4 vs  T3)40% 4.2 (1.6–10.8) 0.005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
may also be correlated with the decreased CEC counts 
associated with higher GvHD grades we documented, although 
with the limitation of the low number of GvHD grade III  
patients and the lack of GvHD grade IV patients in our series. In 
addition to the exhaustion of endothelial cell shedding from 
vascular walls, as a consequence of end-stage endothelial damage 
observed with GvHD worsening, higher CEC counts in low grade 
GvHD may be the result of a putative protective effect of CEC.32 
However, this hypothesis requires in depth investigations and 
potential clinical implications can only be speculative for the 
time being. 
We believe that CEC monitoring in allo-HSCT may facilitate 
diagnosis of acute GvHD and might help identify non-responders 
before the overt development of refractory disease. However, 
before clinical translation, our results need to be confirmed    
in a larger series of GvHD patients. Consequently, it could 
 
 
 
become possible to guide the timely introduction, in non- 
responders, of additional immunosuppressive treatments whereas 
actions might be shifted to less aggressive approaches in 
responders. 
 
Data availability 
The data sets generated during the current study are available 
from the corresponding author on reasonable request. 
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Time points   
GvHD No GvHD 
T1 (pre-conditioning) 
Median (range) 25.5 (2–718) 
Mean ± s.d. 62.7 ± 131.2 
22 (3–786) 
62.7 ± 142.6 
 
T2 (pre-transplant) 
Median (range) 
Mean ± s.d. 
44 (8–718) 
97.1 ± 150.5 
63.5 (3–648) 
99.7 ± 126.5 
 
T3 (engraftment) 
Median (range) 
Mean ± s.d. 
57 (16–295) 
79.2 ± 64.8 
91 (10–436) 
119.8 ± 86.7 
 
T4 (day +28 or GvHD  onset) 
Median (range) 71 (13–658) 
Mean ± s.d. 108.2 ± 121.9 
87 (26–436) 
116.4 ± 84.7 
 
T5 (1 week after steroid treatment) 
Median (range) 48 (6–184) 
Mean ± s.d. 63.9 ± 51.9 
 
T2 vs T1 81.5 (−94 to  4417)    117 (−86 to 10 700)        0.44 
 
 
T3 vs T1 147.5 (−98 to 2848)     314 (−95   to 3500) 0.05 
 
 
T3 vs T2 33  (−89 to 679) 112.5  (−89 to  2933)     0.21 
 
 
T4 vs T1 219.5  (−94  to  1729)   305.5  (−91 to  3043)   0.29 
 
  
 
 
 
 
 
 
 62  (−91  to 1050) 82  (−93  to 2200) 0.74  Characteristics Patients Median P-value 
       CEC/mL (range)  
 13  (−79  to 723) 0  (−70  to 332) 0.026  GvHD grade    
     Grade I 10/39 (26%) 93 (46–299) I vs II  0.66 
 
   
Grade II 
Grade III 
26/39 (67%) 
3/39 (7%) 
64 (13–658) 
36 (34–89) 
vs III 0.05 
vs III 0.11 
 
 
As we previously 
patient series, that 
 
 
reported,19 we fur 
statistically sign 
 
 
ther confirmed, on a larger
ificant higher CEC  counts 
 
Target organs 
Skin (only) 22/39 (56%) 68 (16–658) 
Gut/liver 17/39 (44%) 77 (13–304) 
 
Median  GvHD  onset  (range):  d  +24 (12–113) 
0.36 
(P o0.003) are seen at engraftment  in  patients  with  no  
GvHD  vs  those  who  develop  GvHD.  This  puzzling  finding 
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